223 VERSICAN IS A PROMISING CANDIDATE BIOMARKER IN THE COMBINATION OF DOCETAXEL WITH THALIDOMIDE AS SECOND LINE CHEMOTHERAPY IN CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL RESISTANCE | Zendy

AI Assistant Blog Pricing

223 VERSICAN IS A PROMISING CANDIDATE BIOMARKER IN THE COMBINATION OF DOCETAXEL WITH THALIDOMIDE AS SECOND LINE CHEMOTHERAPY IN CASTRATION-RESISTANT PROSTATE CANCER AFTER DOCETAXEL RESISTANCE

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.